Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
Min Jun, Katie Harris, Hiddo JL Heerspink, Sunil V Badve, Meg J Jardine, Stephen Harrap, Pavel Hamet, Michel Marre, Neil Poulter, Sradha Kotwal, Martin Gallagher, Vlado Perkovic, John Chalmers, Mark Woodward
DIABETES OBESITY & METABOLISM | WILEY | Published : 2021
There are limited data on whether estimated glomerular filtration rate (eGFR) variability modifies the risk of future clinical outcomes in type 2 diabetes (T2D). We assessed the association between 20-month eGFR variability and the risk of major clinical outcomes in T2D among 8241 participants in the ADVANCE trial. Variability in eGFR (coefficient of variation [CVeGFR ]) was calculated from three serum creatinine measurements over 20 months. Participants were classified into three groups by thirds of CVeGFR : low (≤6.4; reference), moderate (>6.4 to ≤12.1) and high (>12.1). The primary outcome was the composite of major macrovascular events, new or worsening nephropathy and all-cause mortali..View full abstract
The ADVANCE trial was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia and from Servier. MJ is supported by a Scientia Fellowship from the University of New South Wales (Sydney, Australia). MW is supported by a National Health and Medical Research Council of Australia Investigator Grant and Program Grant.